Blog
RSS FeedPosted by Michael Wonder on 02 May 2024
PHARMAC publishes minutes from February 2024 PTAC meeting
1 May 2024 - The outcomes from the February 2024 PTAC meeting are now available. ...
Posted by Michael Wonder on 23 Jun 2023
PHARMAC publishes minutes from February 2023 PTAC meeting
21 June 2023 - The meeting was held on 16-17 February 2023 in person and via Zoom. ...
Posted by Michael Wonder on 10 Nov 2022
Decision to fund long-acting paliperidone for people with schizophrenia and ibrutinib for people with chronic lymphocytic leukaemia
10 November 2022 - PHARMAC is pleased to announce a decision to fund two new medicines. ...
Posted by Michael Wonder on 10 Nov 2022
Decision to fund vedolizumab for inflammatory bowel disease and brentuximab for rare lymphomas
10 November 2022 - PHARMAC is pleased to announce a decision to fund two new treatments: vedolizumab for inflammatory bowel ...
Posted by Michael Wonder on 16 Jun 2022
New PHARMAC funded cancer drugs already 'old and cheap', patient advocate Malcolm Mulholland says
16 June 2022 - New cancer drugs that will now be funded by the Government drug buying agency are already ...
Posted by Michael Wonder on 15 Jun 2022
PHARMAC announces first round of medicine funding decisions following $191 million pharmaceutical budget increase
15 June 2022 - PHARMAC today announces the first round of changes to medicines funding following its $191 million pharmaceutical ...
Posted by Michael Wonder on 10 Mar 2022
Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron
10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron. ...
Posted by Michael Wonder on 25 Nov 2021
PHARMAC publishes minutes of August 2021 PTAC meeting
25 November 2021 - Another sparse meeting in terms of the number of new funding applications and funding applications for ...
Posted by Michael Wonder on 03 Feb 2021
First COVID-19 vaccine approved for NZ: How did we get here and what comes next
3 February 2021 - The medicines safety authority has approved the first COVID-19 vaccine for use in New Zealand. ...
Posted by Michael Wonder on 29 Oct 2020
PTAC recommends the reimbursement of osimertinib mesylate for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer
29 October 2020 - PTAC has acknowledged the high unmet clinical need and the high quality, randomised control trial evidence ...
Posted by Michael Wonder on 22 Oct 2020
PHARMAC decision pending on life-changing diabetes medications
22 October 2020 - Government drug-funding agency PHARMAC is expected to decide next week whether it will fund two new ...
Posted by Michael Wonder on 01 Oct 2020
Proposal to decline inactive funding applications
1 October 2020 - To help make the decision-making process clearer, PHARMAC is seeking feedback on a proposal for the ...
Posted by Michael Wonder on 12 May 2020
Decision to fund pancreatic enzymes modified-release granules (Creon Micro)
12 May 2020 - PHARMAC is pleased to announce a decision to fund pancreatic enzymes modified-release granules (Creon Micro) from ...
Posted by Michael Wonder on 22 Apr 2020
PHARMAC back-tracks on plan to fund lung cancer drug Keytruda
22 April 2020 - PHARMAC has frozen plans to fund a lung cancer drug that would have helped at least ...
Posted by Michael Wonder on 16 Apr 2020
Decision to list terbutaline sulphate powder for inhalation (Bricanyl Turbuhaler) in a new model of the Turbuhaler device
16 April 2020 - PHARMAC is pleased to announce that it has made some changes to the listing of terbutaline ...